The Portfolio · BriefLatest →
M&A

AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 23 Jun · 1 min read

Aurobindo Pharma Clears US FTC Hurdle for Lannett Acquisition

Aurobindo's US subsidiary has obtained the required US Federal Trade Commission approval to acquire 100% of Lannett Company LLC, with closing anticipated before the end of June.

What was filed

Aurobindo Pharma Limited informed the exchanges that its wholly owned subsidiary, Aurobindo Pharma USA Inc., has obtained the necessary approval from the US Federal Trade Commission (FTC) for its acquisition of the Lannett business. The disclosure references the company's earlier letter dated July 30, 2025, which announced that Aurobindo Pharma USA Inc. had entered into a definitive agreement with LANNETT SELLER HOLDCO, INC. to acquire 100% of the membership interest in Lannett Company LLC.

Where the deal stands

With the FTC clearance now in hand, the company said it anticipates the transaction will close before the end of this month. Aurobindo added that it will keep the exchanges informed of any future developments in the matter. The filing itself sets out only the regulatory milestone and the expected timing — it does not disclose deal consideration, financing terms, or details of the Lannett business.

Membership interest being acquired
100%

For a holder, the FTC clearance removes a key regulatory condition that had been outstanding since the deal was signed in July 2025, moving the Lannett acquisition close to completion; the filing does not disclose the financial terms or the size of the business being acquired.

More on AUROPHARMA